Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Revenue: 2017-2025

Historic Revenue for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $54.5 million.

  • Puma Biotechnology's Revenue fell 32.36% to $54.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.0 million, marking a year-over-year decrease of 12.96%. This contributed to the annual value of $230.5 million for FY2024, which is 2.19% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Revenue is $54.5 million, which was up 3.89% from $52.4 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Revenue peaked at $98.2 million during Q1 2021, and registered a low of $43.8 million during Q1 2024.
  • Over the past 3 years, Puma Biotechnology's median Revenue value was $54.5 million (recorded in 2025), while the average stood at $56.3 million.
  • In the last 5 years, Puma Biotechnology's Revenue spiked by 91.67% in 2021 and then crashed by 53.41% in 2022.
  • Over the past 5 years, Puma Biotechnology's Revenue (Quarterly) stood at $55.4 million in 2021, then spiked by 58.33% to $87.6 million in 2022, then decreased by 17.65% to $72.2 million in 2023, then declined by 18.15% to $59.1 million in 2024, then crashed by 32.36% to $54.5 million in 2025.
  • Its last three reported values are $54.5 million in Q3 2025, $52.4 million for Q2 2025, and $46.0 million during Q1 2025.